News Digest of July 2019

Posted on: 2019-07-25 12:22:33

July 2, 2019

Genprex, Inc., a clinical stage gene therapy company, today provided an update on development of its lead drug candidate, Oncoprex™ immunogene therapy, in combination with immunotherapy for the treatment of non-small cell lung cancer (NSCLC). (here)

Polo-like kinase 1 inhibition in NSCLC: mechanism of action and emerging predictive biomarkers (here)

 

July 3, 2019

New research shows that antioxidants — notably, vitamin E — promote metastasis in lung cancer through a variety of pathways. The implications from these basic research studies are that taking antioxidants to prevent cancer or after being diagnosed with cancer may be a bad idea. (here)

Albumin-to-alkaline phosphatase ratio at diagnosis predicts survival in patients with metastatic non-small-cell lung cancer (here)

Nearly one-third of patients with cancer who reported that they used complementary and alternative therapies in a nationwide survey did not tell their physicians about the use of those therapies (here)

 

July 4, 2019

Immune Checkpoint Inhibition Efficacy May Vary by EGFR Allele in Lung Cancers (here)

Steroid indication plays key role in link to poor immunotherapy outcome (here)

Tumor Type Determines Response to Gene-Targeting Drugs (here)

Nivolumab plus ipilimumab vs chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumor mutational burden: Patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial (here)

Upfront Next-Generation Sequencing for Lung Cancer: Can It Save Time and Money? (here)

Liquid Biopsy Complements Tissue Biopsy In NSCLC Management (here)

******

Cantargia´s antibody CAN04 (nidanilimab) is investigated in an open label three-armed phase IIa clinical trial, CANFOUR. Here, CAN04 is examined as monotherapy or in chemotherapy combinations in patients with non-small cell lung cancer (NSCLC) or pancreatic cancer (PDAC). (here)

M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer (here)

Dr. Clarke on Available EGFR TKIs in Frontline Treatment of EGFR+ NSCLC (here)

 

July 5, 2019

Conclusions: Tarloxotinib, a prodrug of a potent irreversible inhibitor of EGFR/HER2 in clinical development demonstrated significant activity in CLU-NRG1 patient-derived xenograft model. NRG1 fusions and rearrangements represent an emerging actionable driver alteration in a variety of cancers. Clinical development of Tarloxotinib in NRG1 altered cancers presents an attractive opportunity. (here)

Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC (here)

 

July 6, 2019

Michael Kleinrock, director of research development at the IQVIA Institute for Human Data Science:  With Biomarker Expansion, Combinations and Personalized Medicine Continue to Rise (here)

Dacomitinib (Vizimpro, Pfizer) has been recommended as a first-line treatment option for people with a type of non-small-cell lung cancer (NSCLC), in new National Institute for Health and Care Excellence (NICE) guidance published today.  This once-a-day pill will be available on the NHS for adults with locally advanced or metastatic NSCLC, that has tested positive for the epidermal growth factor receptor (EGFR) mutation. This is a change from the committee’s initial decision which found dacomitinib to not be a cost-effective use of NHS resources. (here)

 

July 7, 2019

Increased 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 activity in response to EGFR signaling contributes to non–small cell lung cancer cell survival (here)

Cantargia confirms enrollment in Phase IIa trial for CAN04 monotherapy.  All the 20 patients for the monotherapy arm of the trial have begun treatment with 10 mg/kg dosage level.  Swedish biotech firm Cantargia has reportedly announced full recruitment of CAN04 monotherapy arm in an existing Phase IIa clinical study in cancer patients. Sources with knowledge on the matter informed that CAN04 (nidanilimab) is an antibody from Cantargia which is being investigated in a three-armed open label Phase IIa trial CANFOUR. Under this, CAN04 is evaluated as monotherapy or in chemotherapy combinations in pancreatic cancer (PDAC) or non-small cell lung cancer (NSCLC) patients. (here)

Adding pemetrexed to continuous maintenance therapy with bevacizumab after induction therapy with carboplatin, pemetrexed and bevacizumab did not significantly improve OS among patients with non-squamous, non-small cell lung cancer without sensitizing EGFR mutations, according to results of the phase 3 COMPASS trial.  Although the trial failed to meet its primary endpoint of OS in the overall population, the addition of pemetrexed to continuous maintenance therapy with bevacizumab (Avastin, Genentech) did significantly prolong PFS, as well as OS among patients aged younger than 70 years and those with wild-type EGFR mutations. (here)

 

July 23, 2019

 

[HTML] Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation

J Chantharasamee, N Poungvarin, P Danchaivijitr… - BMC cancer, 2019

Uncommon epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a rare subset of NSCLC. The aim of this study was to investigate the prevalence, characteristics, and clinical outcomes of …

[PDF] Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model

B Sarcar, NT Gimbrone, G Wright, LL Remsing Rix… - FEBS Open Bio, 2019

… although these findings are not universal [8, 9]. Unlike EGFR exon 19 deletions and L858R mutants, most NSCLCs with EGFR exon 20 insertion mutations don't respond to gefitinib
or erlotinib and the mechanism of drug resistance remains unresolved [2]. Page 4 …

Mechanisms of Acquired Resistance to Targeted Therapy in NSCLC: Role of Repeat Biopsy and Nursing Considerations

E Duffield - Targeted Therapies in Lung Cancer: Management …, 2019… Oncotarget. 2017;8(41):71358–70.CrossRefGoogle Scholar. 20. Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet …

Methods For Finding Genome Rearrangments From Sequencing Data

A Grigoriev, SD Smith - US Patent App. 16/241,725, 2019

The present disclosure generally relates to finding genome rearrangements from sequencing data. DNA sequence analysis systems and methods directed to identifying all sequence variants in a genome are identified.

Celebrating a curious mind: Steven Keating 1988-2019.

MBGallagher - MIT News. July 22, 2019

Celebrating a curious mind: Steven Keating 1988-2019. Steven Keating SM'12, PhD '16 inspired millions with his research-driven approach to battling cancer and his advocacy for open patient health data.